Neurology Central

NICE issues draft guidance against Aimovig® (erenumab)

In a draft guidance issued this week, NICE (London, UK) has recommended against the routine NHS use of Aimovig® (erenumab) for the prevention of migraine in adults who experience at least four migraine days per month, and where at least three other preventive treatments haven’t worked.

Previous evidence has demonstrated that Aimovig is a clinically effective treatment, and the drug has previously received an EMA license, a positive CHMP opinion and gained US FDA approval.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.